(Total Views: 299)
Posted On: 02/23/2019 11:41:45 AM
Post# of 63818
GNCP - - Revenues projected for the period April 2019 to March 2020 as NO LESS than $12 million
GNCC Capital, Inc. Acquires BioCann Pharma S.A.S.
- The Purchase Price of $120 million includes very stringent Net Revenue Warranties and appropriate performance penalties as agreed upon by the Sellers of BioCann. BioCann has warranted Net Attributable Revenues of not less than $12 million for the period April 1, 2019 to March 31, 2020. These are explained in very specific detail in the referenced Filing. All of the Equity Instruments being issued in settlement of this acquisition are restricted from any sale and/or conversion for a period of not less than 18 (Eighteen) months. The shares of restricted Common Stock were issued at a price of $0.03 (Three cents) per share.
https://www.prnewswire.com/news-releases/gncc...99508.html
https://backend.otcmarkets.com/otcapi/company...41/content
GNCC Capital, Inc. Acquires BioCann Pharma S.A.S.
- The Purchase Price of $120 million includes very stringent Net Revenue Warranties and appropriate performance penalties as agreed upon by the Sellers of BioCann. BioCann has warranted Net Attributable Revenues of not less than $12 million for the period April 1, 2019 to March 31, 2020. These are explained in very specific detail in the referenced Filing. All of the Equity Instruments being issued in settlement of this acquisition are restricted from any sale and/or conversion for a period of not less than 18 (Eighteen) months. The shares of restricted Common Stock were issued at a price of $0.03 (Three cents) per share.
https://www.prnewswire.com/news-releases/gncc...99508.html
https://backend.otcmarkets.com/otcapi/company...41/content
(0)
(0)
